

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Christian Wissgott

Page 1/2

Tuesday, January 30, 2018

ROOM 1 - MAIN ARENA 1

- 09:30 – 11:00** **Latest results with new technologies for femoropopliteal obstructions: drug-eluting devices, atherectomy and new implants**
MODERATOR:
Dierk Scheinert
PANEL:
Marianne Brodmann
Thomas Zeller
Steven Kum
Wei Guo
- 09:30 – 09:35 EFFPAC–RCT: Final 6-months results with the Luminor DCB in femoropopliteal lesions
Dierk Scheinert
- 09:35 – 09:40 ILLUMENATE EU RCT: 2-year results with the Stellarex DCB in femoropopliteal lesions
Marianne Brodmann
- 09:40 – 09:45 FIRST TIME DATA RELEASE: CONSEQUENT RCT: 2-year results with the SeQuent Please OTW DCB
Thomas Albrecht
- 09:45 – 09:50 FIRST TIME DATA RELEASE: IN.PACT Japan RCT of DCB vs. PTA: 2-year results
Osamu Iida
- 09:50 – 09:55 FIRST TIME DATA RELEASE: ILLUMENATE GLOBAL: 2-year results of the Stellarex DCB in femoropopliteal lesions
Thomas Zeller
- 09:55 – 10:00 DANCE trial (ATX and PTA groups) – 2-year results
George Adams
- 10:00 – 10:05 Long term durability of DCB treatment in the SFA: 4-year results of the IN.PACT SFA study
John Laird
- 10:05 – 10:10 Outcomes of DCB use in real-world patients: 2-year results from the IN.PACT global registry
Marianne Brodmann
- 10:10 – 10:15 FIRST TIME DATA RELEASE: LUTONIX long lesion study: 2-year outcomes
Martin Banyai

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Christian Wissgott

Page 2/2

Tuesday, January 30, 2018

- | | |
|---------------|--|
| 10:15 – 10:20 | FIRST TIME DATA RELEASE: COMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions
Dierk Scheinert |
| 10:20 – 10:25 | FIRST TIME DATA RELEASE: Outcomes of DCB use in femoropopliteal lesions of patients with CLI (RCC4/5): Subgroup analysis of IN.PACT global study
Michel Reijnen |
| 10:25 – 10:35 | PROMISE AND LIMITATIONS OF DCB – WHAT HAVE WE LEARNED? |
| 10:25 – 10:30 | DCB from a preclinical perspective: The relevance of paclitaxel dose and coating integrity
Juan Fernando Granada Solis |
| 10:30 – 10:35 | DCB from a clinical perspective: What is proven and where are the open questions and limitations?
Marc Bosiers |
| 10:35 – 10:40 | Panel discussion |
| 10:40 – 10:45 | Update on the TOBA studies in the femoropopliteal arteries
Christian Wissgott |
| 10:45 – 10:50 | FIRST TIME DATA RELEASE: LOCOMOTIVE All Comers Study with the VascuFlex Multi-LOC spot stenting device: 12-month results
Klaus Amendt |
| 10:50 – 10:55 | FIRST TIME DATA RELEASE: 1-year results from the MIMICS-2 Study; US, German, and Japanese experience with the BioMimics 3D stent
Thomas Zeller |
| 10:55 – 11:00 | Discussion and conclusion |

We are asking all faculty members to strictly respect the given time limits.